Literature DB >> 19841986

Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.

Makoto Suzuki1, Hironobu Wada, Mitsuru Yoshino, Lei Tian, Hisayuki Shigematsu, Hidemi Suzuki, Mahmoud Alaa, Hajime Tamura, Taiki Fujiwara, Kaoru Nagato, Shinichiro Motohashi, Yasumitsu Moriya, Hidehisa Hoshino, Shigetoshi Yoshida, Kiyoshi Shibuya, Kenzo Hiroshima, Yukio Nakatani, Ichiro Yoshino.   

Abstract

BACKGROUND: The aim of this study was to evaluate the molecular influence of chronic obstructive pulmonary diseases (COPD) on the pathogenesis of non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: The methylation profiles of 12 genes, and the epidermal growth factor receptor (EGFR) and KRAS mutations were determined for samples from 229 NSCLC patients. In addition, protein expression of EGFR and HER2 in 116 NSCLCs was analyzed based on the presence or absence of COPD.
RESULTS: IL-12Rbeta2 and Wif-1 methylation and HER2 overexpression were more frequent events in the COPD group. Eighty nonmalignant lung tissues had no correlation with any molecular changes between the COPD and the non-COPD group. EGFR mutation was significantly higher in the non-COPD group, while EGFR expression was inversely correlated with %FEV1.0. In the COPD group, unmethylated SPARC and sFRP-2 genes or a negative CpG island methylator phenotype (CIMP) was a negative prognostic factor, while methylation of p16(INK4A) and WNT antagonist genes was a negative prognostic factor in the non-COPD group.
CONCLUSIONS: Novel characteristics of COPD-related NSCLC were identified by examination of methylation profiles and alterations of EGFR signaling. In consideration of the high sensitivity to smoking in patients with COPD, NSCLC with COPD might be a distinct population of smoke-related NSCLC, the genetic profile of which is quite different from non-COPD NSCLC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841986     DOI: 10.1245/s10434-009-0739-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  28 in total

1.  Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.

Authors:  Young Wha Koh; Sung-Min Chun; Young-Soo Park; Joon Seon Song; Geon Kook Lee; Shin Kwang Khang; Se Jin Jang
Journal:  Tumour Biol       Date:  2016-02-11

Review 2.  Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases.

Authors:  Isaac K Sundar; Hongwei Yao; Irfan Rahman
Journal:  Antioxid Redox Signal       Date:  2012-11-06       Impact factor: 8.401

Review 3.  Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigenetics.

Authors:  Isaac K Sundar; Nandita Mullapudi; Hongwei Yao; Simon D Spivack; Irfan Rahman
Journal:  Curr Opin Pulm Med       Date:  2011-07       Impact factor: 3.155

4.  Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients.

Authors:  James B Rawson; Michael Manno; Miralem Mrkonjic; Darshana Daftary; Elizabeth Dicks; Daniel D Buchanan; H Banfield Younghusband; Patrick S Parfrey; Joanne P Young; Aaron Pollett; Roger C Green; Steven Gallinger; John R McLaughlin; Julia A Knight; Bharati Bapat
Journal:  Carcinogenesis       Date:  2011-02-08       Impact factor: 4.944

5.  Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer.

Authors:  Mathewos Tessema; Christin M Yingling; Maria A Picchi; Guodong Wu; Yushi Liu; Joel L Weissfeld; Jill M Siegfried; Yohannes Tesfaigzi; Steven A Belinsky
Journal:  J Thorac Oncol       Date:  2015-08       Impact factor: 15.609

6.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer.

Authors:  Mónica Castro; Laura Grau; Patricia Puerta; Liliana Gimenez; Julio Venditti; Silvia Quadrelli; Marta Sánchez-Carbayo
Journal:  J Transl Med       Date:  2010-09-17       Impact factor: 5.531

7.  Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis.

Authors:  Yali Liang; Lianping He; Hui Yuan; Yuelong Jin; Yingshui Yao
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

8.  FACER: comprehensive molecular and functional characterization of epigenetic chromatin regulators.

Authors:  Jianping Lu; Juan Xu; Junyi Li; Tao Pan; Jing Bai; Liqiang Wang; Xiyun Jin; Xiaoyu Lin; Yunpeng Zhang; Yongsheng Li; Nidhi Sahni; Xia Li
Journal:  Nucleic Acids Res       Date:  2018-11-02       Impact factor: 16.971

9.  Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients.

Authors:  Mathewos Tessema; Dereje D Tassew; Christin M Yingling; Kieu Do; Maria A Picchi; Guodong Wu; Hans Petersen; Scott Randell; Yong Lin; Steven A Belinsky; Yohannes Tesfaigzi
Journal:  Lung Cancer       Date:  2020-05-25       Impact factor: 5.705

Review 10.  The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis.

Authors:  Xiang-Bin Xing; Wei-Bin Cai; Liang Luo; Long-Shan Liu; Hui-Juan Shi; Min-Hu Chen
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.